Zydus Lifesciences Q1 FY27: Revenue +22%, profit -36%

Results snapshot: strong sales, weaker bottom line

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) reported a mixed set of numbers for Q1 FY27, pairing solid revenue growth with a sharp decline in profitability. Consolidated revenue from operations rose to ₹8,017.0 crore, up 22.0% year-on-year and 5.7% sequentially. Over the same period, reported net profit fell 35.9% year-on-year to ₹939.8 crore, reflecting cost pressure and other impacts cited in the earnings discussion. The company presented the results on August 11, 2026, alongside its Q1 FY27 earnings call.

The quarter’s headline message was that growth across key businesses did not translate into stronger earnings. The company flagged that profitability came under pressure during the quarter even as India formulations, consumer wellness, and international markets supported the top line. Zydus also noted that net profit was affected by higher amortization and a one-time tax disallowance linked to thin capitalization rules in the UK.

Revenue growth drivers mentioned by the company

Management attributed the 22% year-on-year rise in revenue to robust performance across India formulations, consumer wellness, and international markets. While the company did not provide segment-level numbers in the provided excerpt, it reiterated that multiple business lines contributed to the expansion. Sequentially, revenue improved 5.7% from Q4 FY26.

Zydus also described consolidated revenues as ₹80.2 billion in the earnings call context, which aligns with ₹8,017.0 crore in the quarterly table. That scale matters because it shows the company is still delivering growth in a competitive environment, even as costs and margin factors shaped the earnings outcome.

EBITDA falls and margin compresses sharply

Operating profitability weakened in Q1 FY27. EBITDA declined 7.6% year-on-year to ₹1,929.4 crore. The EBITDA margin contracted to 24.1%, compared with 31.8% in Q1 FY26, a decline of 770 basis points.

On a sequential basis, the pressure was also visible. EBITDA fell 24.5% versus Q4 FY26, while the EBITDA margin dropped from 33.7% in Q4 FY26 to 24.1% in Q1 FY27. The earnings call description still referred to the performance as “robust” at the operating level, but the reported margin shift indicates a meaningful change in profitability profile versus both the previous quarter and the prior year.

Net profit decline: amortization and UK tax disallowance

Zydus’ reported net profit fell 35.9% year-on-year to ₹939.8 crore, and 26.1% sequentially versus Q4 FY26. The company linked the profit decline to higher amortization and a one-time tax disallowance due to thin capitalization rules in the UK.

In the Q&A, the CFO said the effective tax rate for Q1 was close to 27% because of disallowance of items under the UK thin cap rule, and that otherwise it would have been around 25%. For FY27, the effective tax rate was guided at around 25%, while the cash component was indicated to be lower at roughly 12-15%. The CFO added that from next year, the tax rate should be 25% with a full cash component.

Gross margin and gross profit movement

The quarterly table showed gross profit of ₹5,777.2 crore in Q1 FY27, up 20.8% year-on-year. However, gross margin slipped to 72.1% from 72.8% in Q1 FY26. Sequentially, gross margin declined from 74.0% in Q4 FY26 to 72.1% in Q1 FY27.

This indicates that while absolute gross profit increased with sales, margin headwinds were visible even before operating expenses. The earnings commentary also referenced elevated expenses as a key factor that offset revenue growth and weighed on net profit.

R&D spends and operating cost context

Research and development spend increased to ₹642.4 crore in Q1 FY27 from ₹485.6 crore in Q1 FY26, a rise of 32.3% year-on-year. Sequentially, R&D was down 8.0% from Q4 FY26 (₹698.2 crore).

While the excerpt does not break down other cost lines, the combination of higher R&D and lower operating margins provides context for why EBITDA fell despite revenue growth. For investors, the key point is that the quarter reflected a different cost intensity versus last year’s comparable period.

Seasonality impact: summer showers hit seasonal brands

Zydus also flagged a specific consumption-related headwind in the quarter. Seasonal brands declined by 12% due to frequent summer showers in eastern and northern India, which disrupted the usual summer consumption pattern.

This detail matters because it frames part of the quarter’s pressure as demand and seasonality-driven rather than purely execution-related. It also highlights that consumer-facing parts of the portfolio can see short-term volatility from weather patterns.

Leverage: net debt to EBITDA moves higher

The reported net debt to EBITDA stood at 0.70x in Q1 FY27, compared with (0.80x) in Q1 FY26 and 0.49x in Q4 FY26. The table explicitly marked the ratio as “higher” versus both comparison periods.

While the ratio remains below 1x, the direction of movement is notable given the quarter’s margin compression. Investors typically track this metric closely when EBITDA is volatile, as it changes the pace at which leverage ratios can shift.

Key numbers table (all figures in ₹ crore)

Market impact and investor focus areas

From a market lens, the quarter offers two clear markers: growth remains strong, but earnings quality and margins need close monitoring. Revenue growth of 22% year-on-year is significant for a large pharmaceutical company, but the 770 basis point EBITDA margin contraction and 35.9% decline in net profit are equally material.

The investor conversation is also shaped by tax-related items. The UK thin capitalization disallowance contributed to a higher effective tax rate in Q1, according to the CFO, and management guidance suggests normalization around 25% for FY27. Separately, higher amortization also impacted profit, and the company discussed net profit “excluding amortization of acquired brands” growing 26.5% for the quarter in another excerpt included in the provided material.

An investor post on X cited the company’s market capitalization at ₹1,11,241.63 crore alongside the quarter’s topline growth and profit decline, reflecting the immediate market narrative: revenue momentum versus profitability pressure.

Analysis: why this quarter matters

Q1 FY27 highlights how earnings can diverge from revenue when margins compress and tax or amortization impacts rise. Even with strong sales growth, EBITDA fell and the net profit decline was steeper, suggesting that investors may focus more on operating leverage, cost control, and normalization of one-off items in subsequent quarters.

The R&D increase year-on-year is also a key datapoint because it indicates higher investment intensity, which can be strategically important but can weigh on near-term margins. Finally, the seasonality effect on seasonal brands underscores that consumer and wellness categories can introduce volatility unrelated to core pharma demand.

Conclusion: growth intact, profitability under scrutiny

Zydus Lifesciences delivered a strong revenue quarter in Q1 FY27, with operations revenue at ₹8,017 crore, but reported profit and margins weakened materially. Management attributed the profit decline to higher amortization and a one-time UK tax disallowance, while also noting weather-driven softness in seasonal brands. The next set of updates investors are likely to track includes margin trajectory, tax-rate normalization as guided, and any further commentary in the full earnings call transcript referenced by the company.